The company uses Targeted Protein Degradation (TPD) technology to overcome the limitations of small molecules and degrade virtually any intracellular protein, including the "undruggable proteome". As a publicly-listed drug discovery and development company, Captor Therapeutics aims to transform the lives of patients with poorly treatable conditions by creating new drug candidates that have the potential to cure these diseases. Their innovative technology is perfectly suited to ease the burden of patients suffering from cancer, autoimmunity, and neurodegenerative diseases.